Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 672
Gene Symbol: BRCA1
BRCA1
0.600 GeneticVariation disease BEFREE Retrospective studies suggest a survival benefit when platinum-based chemotherapy is administered to patients with pancreatic cancer harbouring a germline mutation in BRCA1, BRCA2 or PALB2 (mut-positive PDAC). 31787751 2020
Entrez Id: 672
Gene Symbol: BRCA1
BRCA1
0.600 GeneticVariation disease BEFREE Genotype-phenotype correlation in BRCA1/2 mutation-associated pancreatic cancer. 31787750 2020
Entrez Id: 672
Gene Symbol: BRCA1
BRCA1
0.600 GeneticVariation disease BEFREE Olaparib is a PARP inhibitor (PARPi).For patients bearing BRCA1 or BRCA2 mutations, olaparib is approved to treat ovarian cancer and in clinical trials to treat breast and pancreatic cancers. 30660828 2019
Entrez Id: 672
Gene Symbol: BRCA1
BRCA1
0.600 GeneticVariation disease BEFREE The multicenter surveillance program included asymptomatic HRIs with familial (FPC) or genetic frailty (GS: BRCA1/2, p16/CDKN2A, STK11/LKB1or PRSS1, mutated genes) predisposition to PC. 30538291 2019
Entrez Id: 672
Gene Symbol: BRCA1
BRCA1
0.600 GeneticVariation disease BEFREE In conclusion, families with a positive history of PC and patients with BRCA 1 or 2 mutations should be monitored. 31118690 2019
Entrez Id: 672
Gene Symbol: BRCA1
BRCA1
0.600 Biomarker disease BEFREE Comparison of Practice Guidelines, BRCAPRO, and Genetic Counselor Estimates to Identify Germline BRCA1 and BRCA2 Mutations in Pancreatic Cancer. 29441441 2018
Entrez Id: 672
Gene Symbol: BRCA1
BRCA1
0.600 GeneticVariation disease BEFREE Comparing 3030 case patients with pancreatic cancer (43.2% female; 95.6% non-Hispanic white; mean age at diagnosis, 65.3 [SD, 10.7] years) with reference controls, significant associations were observed between pancreatic cancer and mutations in CDKN2A (0.3% of cases and 0.02% of controls; odds ratio [OR], 12.33; 95% CI, 5.43-25.61); TP53 (0.2% of cases and 0.02% of controls; OR, 6.70; 95% CI, 2.52-14.95); MLH1 (0.13% of cases and 0.02% of controls; OR, 6.66; 95% CI, 1.94-17.53); BRCA2 (1.9% of cases and 0.3% of controls; OR, 6.20; 95% CI, 4.62-8.17); ATM (2.3% of cases and 0.37% of controls; OR, 5.71; 95% CI, 4.38-7.33); and BRCA1 (0.6% of cases and 0.2% of controls; OR, 2.58; 95% CI, 1.54-4.05). 29922827 2018
Entrez Id: 672
Gene Symbol: BRCA1
BRCA1
0.600 GeneticVariation disease BEFREE BRCA1/2 genes are the most commonly mutated pancreatic cancer susceptibility genes that should be considered in all pancreatic cancer cases with young age at onset or a family history of cancer. 29940740 2018
Entrez Id: 672
Gene Symbol: BRCA1
BRCA1
0.600 GeneticVariation disease BEFREE We found rs1799966 on BRCA1 was associated with poor prognosis of pancreatic cancer patients with hazard ratio being 1.23 (95% CI: 1.09-1.40, P = 0.0010). 28415599 2017
Entrez Id: 672
Gene Symbol: BRCA1
BRCA1
0.600 GeneticVariation disease BEFREE Results Thirty-three (3.9%; 95% CI, 3.0% to 5.8%) of 854 patients with pancreatic cancer had a deleterious germline mutation, 31 (3.5%) of which affected known familial pancreatic cancer susceptibility genes: BRCA2 (12 patients), ATM (10 patients), BRCA1 (3 patients), PALB2 (2 patients), MLH1 (2 patients), CDKN2A (1 patient), and TP53 (1 patient). 28767289 2017
Entrez Id: 672
Gene Symbol: BRCA1
BRCA1
0.600 Biomarker disease BEFREE BRCA1 was found to have the same association with PC as BRCA2, which appears unique to our population. 26727920 2016
Entrez Id: 672
Gene Symbol: BRCA1
BRCA1
0.600 GeneticVariation disease BEFREE Pancreatic cancer with a BRCA1/2 mutation is a small subgroup with a promising therapeutic strategy. 26402249 2015
Entrez Id: 672
Gene Symbol: BRCA1
BRCA1
0.600 GeneticVariation disease BEFREE The SIR for all BRCA1/2 mutation carriers compared with the rates in the general population were elevated for pancreatic cancer [2.97 (95 % CI 1.83-4.29)] and breast cancer [16.44 (95 % CI 9.65-26.24)]. 25788227 2015
Entrez Id: 672
Gene Symbol: BRCA1
BRCA1
0.600 GeneticVariation disease BEFREE Targeting defects in the DNA repair machinery of neoplastic cells, for example, those due to inactivating BRCA1 and/or BRCA2 mutations, has been used for developing new therapies in certain types of breast, ovarian and pancreatic cancers. 26511885 2015
Entrez Id: 672
Gene Symbol: BRCA1
BRCA1
0.600 Biomarker disease CTD_human Common variation at 2p13.3, 3q29, 7p13 and 17q25.1 associated with susceptibility to pancreatic cancer. 26098869 2015
Entrez Id: 672
Gene Symbol: BRCA1
BRCA1
0.600 GeneticVariation disease BEFREE BRCA1 and BRCA2 germline mutations are frequently demonstrated in both high-risk pancreatic cancer screening and pancreatic cancer cohorts. 24737347 2014
Entrez Id: 672
Gene Symbol: BRCA1
BRCA1
0.600 Biomarker disease BEFREE Considering truncating mutations, the prevalence rate of our population of BRCA1/2-negative breast cancer patients with pancreatic cancer is 1.5%. 23935836 2013
Entrez Id: 672
Gene Symbol: BRCA1
BRCA1
0.600 Biomarker disease BEFREE Germ-line mutations in PALB2 lead to a familial predisposition to breast and pancreatic cancer or to Fanconi Anemia subtype N. PALB2 performs its tumor suppressor role, at least in part, by supporting homologous recombination-type double strand break repair (HR-DSBR) through physical interactions with BRCA1, BRCA2, and RAD51. 23657012 2013
Entrez Id: 672
Gene Symbol: BRCA1
BRCA1
0.600 GeneticVariation disease BEFREE The most important genes with variants increasing risk for pancreatic cancer include BRCA1, BRCA2, PALB2, ATM, CDKN2A, APC, MLH1, MSH2, MSH6, PMS2, PRSS1, and STK11. 23187834 2013
Entrez Id: 672
Gene Symbol: BRCA1
BRCA1
0.600 GeneticVariation disease BEFREE Germline mutations in BRCA1 and BRCA2 are associated with an increased risk of pancreatic cancer. 23456555 2013
Entrez Id: 672
Gene Symbol: BRCA1
BRCA1
0.600 GeneticVariation disease BEFREE However, a subset of pancreatic cancer is attributable to known inherited cancer predisposition syndromes, including several hereditary breast cancer genes (BRCA1, BRCA2, and PALB2), CDKN2A, hereditary pancreatitis, hereditary nonpolyposis colorectal cancer, and Peutz-Jeghers syndrome. 22846737 2013
Entrez Id: 672
Gene Symbol: BRCA1
BRCA1
0.600 GeneticVariation disease BEFREE A clinical database review (2000-2009) identified 211 Ashkenazi Jewish (AJ) BC probands who 1) underwent BRCA1/2 mutation analysis by full gene sequencing or directed testing for Ashkenazi founder mutations (BRCA1: 185delAG and 5382insC; BRCA2: 6174delT) and 2) had a FH of PC in a first-, second-, or third-degree relative. 21598239 2012
Entrez Id: 672
Gene Symbol: BRCA1
BRCA1
0.600 GeneticVariation disease BEFREE As it is well known that the prevalence of gene mutations varies between different populations, we studied the prevalence of PALB2 mutations in a Dutch cohort of non-BRCA1/2 familial PC (FPC) families and in non-BRCA1/2 familial BC (FBC) families with at least one PC case. 22166947 2012
Entrez Id: 672
Gene Symbol: BRCA1
BRCA1
0.600 GeneticVariation disease BEFREE We also reviewed the pedigrees of 8140 pedigrees with a BRCA1 or a BRCA2 mutation for those with a case of pancreatic cancer. 23099806 2012
Entrez Id: 672
Gene Symbol: BRCA1
BRCA1
0.600 Biomarker disease BEFREE PALB2 mutation analysis was performed in 94 non-BRCA1/2 breast cancer patients with a personal or family history of pancreatic cancer. 21365267 2011